Search

Your search keyword '"Jhingran, Anuja"' showing total 29 results
Start Over Author "Jhingran, Anuja" Publisher bmj
29 results on '"Jhingran, Anuja"'

4. Executive summary of the American Radium Society appropriate use criteria for management of uterine clear cell and serous carcinomas

Author

Sherertz, Tracy, primary, Jhingran, Anuja, additional, Biagioli, Matthew, additional, Gaffney, David, additional, Elshaikh, Mohamed, additional, Coleman, Robert L, additional, Harkenrider, Matthew, additional, Kidd, Elizabeth A, additional, Jolly, Shruti, additional, Yashar, Catheryn, additional, Portelance, Lorraine, additional, Wahl, Andrew, additional, Venkatesan, Aradhana, additional, Li, Linna, additional, and Small, William, additional

Published
2022
Full Text
View/download PDF

9. Cervical cancer in Eastern Europe: review and proceedings from the Cervical Cancer Research Conference

Author

Small Jr, William, primary, Peltecu, Gheorghe, additional, Puiu, Anastasia, additional, Corha, Andrei, additional, Cocîrṭă, Elena, additional, Cigăran, Ruxandra Gabriela, additional, Plante, Marie, additional, Jhingran, Anuja, additional, Stang, Kyle, additional, Gaffney, David, additional, Bacon, Monica, additional, and McCormack, Mary, additional

Published
2020
Full Text
View/download PDF

16. Cervix Cancer Research Network (CCRN): Improving Access to Cervix Cancer Trials on a Global Scale

Author

Gaffney, David, primary, Small, Bill, additional, Kitchener, Henry, additional, Young Ryu, Sang, additional, Viswanathan, Akila, additional, Trimble, Ted, additional, Covens, Al, additional, Wilailak, Sarikapan, additional, Lertkhachonsuk, Arb-aroon, additional, Sitathanee, Chomporn, additional, Mahantshetty, Umesh, additional, Fisher, Brandon, additional, Springer, Susan, additional, Pollatz, Thomas, additional, Spiller, Antonius, additional, Bacon, Monica, additional, and Jhingran, Anuja, additional

Published
2016
Full Text
View/download PDF

17. Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future

Author

Sagae, Satoru, primary, Monk, Bradley J., additional, Pujade-Lauraine, Eric, additional, Gaffney, David K., additional, Narayan, Kailash, additional, Ryu, Sang Young, additional, McCormack, Mary, additional, Plante, Marie, additional, Casado, Antonio, additional, Reuss, Alexander, additional, Chávez-Blanco, Adriana, additional, Kitchener, Henry, additional, Nam, Byung-Ho, additional, Jhingran, Anuja, additional, Temkin, Sarah, additional, Mileshkin, Linda, additional, Berns, Els, additional, Scholl, Suzy, additional, Doll, Corinne, additional, Abu-Rustum, Nadeem R., additional, Lecuru, Fabrice, additional, and Small, William, additional

Published
2016
Full Text
View/download PDF

22. Ribonucleotide Reductase Expression in Cervical Cancer

Author

Kunos, Charles A., primary, Winter, Kathryn, additional, Dicker, Adam P., additional, Small, William, additional, Abdul-Karim, Fadi W., additional, Dawson, Dawn, additional, Jhingran, Anuja, additional, Valicenti, Richard, additional, Weidhaas, Joanne B., additional, and Gaffney, David K., additional

Published
2013
Full Text
View/download PDF

23. COX-2 Expression and Survival in Patients With Locally Advanced Cervical Cancer Treated With Chemoradiotherapy and Celecoxib: A Quantitative Immunohistochemical Analysis of RTOG C0128

Author

Doll, Corinne M., primary, Winter, Kathryn, additional, Gaffney, David K., additional, Ryu, Janice K., additional, Jhingran, Anuja, additional, Dicker, Adam P., additional, Weidhaas, Joanne B., additional, Miller, Brigitte E., additional, and Magliocco, Anthony M., additional

Published
2013
Full Text
View/download PDF

28. Impact of pelvic radiation therapy in patients with early neuroendocrine cervical carcinoma and no residual disease in the radical hysterectomy specimen: a NeCTuR study.

Author

Khurana N, Frumovitz M, Flores Legarreta A, Ramalingam P, Jhingran A, Bhosale P, Saab R, Gonzales NRR, Chisholm GB, and Salvo G

Subjects
Humans, Female, Middle Aged, Adult, Radiotherapy, Adjuvant methods, Neoplasm Staging, Neoplasm Recurrence, Local pathology, Retrospective Studies, Neoplasm, Residual pathology, Uterine Cervical Neoplasms pathology, Uterine Cervical Neoplasms radiotherapy, Uterine Cervical Neoplasms surgery, Uterine Cervical Neoplasms mortality, Hysterectomy methods, Carcinoma, Neuroendocrine pathology, Carcinoma, Neuroendocrine radiotherapy, Carcinoma, Neuroendocrine surgery, Carcinoma, Neuroendocrine mortality
Abstract

Objective: The impact of adjuvant pelvic radiation therapy on the rate and location of recurrences was evaluated in patients with early-stage (IA1-IB2) neuroendocrine cervical carcinoma who underwent prior conization or polypectomy with no residual disease and negative nodes in the subsequent upfront radical hysterectomy specimen. As a secondary objective, disease-free and overall survival were analyzed., Methods: We searched the Neuroendocrine Cervical Tumor Registry (NeCTuR) to identify patients with clinical early-stage neuroendocrine cervical carcinoma with no residual disease in the specimen from upfront radical surgery and negative nodes. Patients who received pelvic radiation therapy were compared with those who did not, regardless of whether they received adjuvant chemotherapy., Results: Twenty-seven patients met the inclusion criteria, representing 17% of all patients with clinical early-stage disease who underwent upfront radical hysterectomy included in the NeCTuR registry. The median age was 36.0 years (range 26.0-51.0). Six (22%) patients had stage IA, 20 (74%) had stage IB1, and one (4%) had stage IB2 disease. Seven (26%) patients received adjuvant radiation therapy and 20 (74%) did not. All seven patients in the radiation group and 14 (70%) in the no-radiation group received adjuvant chemotherapy (p=0.16). Fifteen percent (4/27) of patients had a recurrence, 14% (1/7) in the radiation group and 15% (3/20) in the no-radiation group (p=0.99). In the radiation group the recurrence was outside the pelvis, and in the no-radiation group, 67% (2/3) recurred outside the pelvis and 33% (1/3) recurred both inside and outside the pelvis (p=0.99). In the radiation group the 5-year disease-free and overall survival rates were 100% while, in the no-radiation group, the 5-year disease-free and overall survival rates were 81% (95% CI 61% to 100%) (p=0.99) and 80% (95% CI 58% to 100%) (p=0.95), respectively., Conclusions: For patients with no residual disease and negative nodes in the upfront radical hysterectomy specimen, our study did not find that pelvic radiation therapy improves survival., Competing Interests: Competing interests: MF has research support from AkesoBio and is a speaker/consultant for Stryker. The other authors have no competing interests., (© IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2024
Full Text
View/download PDF

29. Cervical cancer in Eastern Europe: review and proceedings from the Cervical Cancer Research Conference.

Author

Small W Jr, Peltecu G, Puiu A, Corha A, Cocîrṭă E, Cigăran RG, Plante M, Jhingran A, Stang K, Gaffney D, Bacon M, and McCormack M

Subjects
Europe, Eastern, Female, Humans, Uterine Cervical Neoplasms epidemiology
Abstract

Cervical cancer is the third most common cancer among women worldwide, with a disproportionately high burden of disease in less-developed regions of the world. The Cervix Cancer Research Network was founded by the Gynecologic Cancer InterGroup with a mission to improve outcomes in cervical cancer by enhancing international access to clinical trials, specifically in under-represented, underdeveloped areas. The Cervix Cancer Research Network held its third international educational symposium in Bucharest in 2018 and is the subject of this report. The purpose of this symposium was to advance the international understanding of cervical cancer treatment patterns, to foster recruitment to Cervix Cancer Research Network clinical trials, and identify key Cervix Cancer Research Network clinical trial concepts to improve cervical cancer care worldwide., Competing Interests: Competing interests: MM reports other support from Roche and personal fees from Astra Zeneca; WSJ reports personal fees from Carl Zeiss and other support from NRG Oncology and Merck., (© IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results